Elixinol Wellness Limited (ASX: EXL / OTC: ELLXF) – Ramping Up Revenue While Slashing Costs
Highlights In 2022, revenue fell 24% YoY to $7.1M, but beat our estimate by 8%. Revenue declined...
Read MoreHighlights In 2022, revenue fell 24% YoY to $7.1M, but beat our estimate by 8%. Revenue declined...
Read MoreHighlights This company develops and sells hemp-derived CBD nutraceutical, cosmetic, and food...
Read MoreHighlights The U.S. House of Representatives announced plans to vote on the MORE Act this week;...
Read MoreHighlights In Q2-FY2022 (quarter ended December 2021), this company reported $3.2M in revenue, up...
Read MoreHighlights Q3 revenue increased 28% YoY, but declined 4% QoQ, and fell well below our expectations...
Read MoreHighlights Q3-2022 (quarter ended October 2021) revenue was up 44% YoY, driven by store expansion...
Read MoreHighlights Generated $1.14M in revenue in Q1-FY2022 (quarter ended October 31, 2021), up 83% YoY,...
Read MoreHighlights In Q1-FY2022 (quarter ended September 30, 2021), AYUR reported $1.9M in revenue, up...
Read MoreHighlights Q3 revenue was $8M (in line with our expectations), up 29% YoY, and 16% QoQ due to the...
Read MoreHighlights Reported Q3 revenue of $15.2M, up 16% YoY, but down 9% QoQ due to weaker revenue from...
Read More